Real-World Clinical Outcomes with First-Line Systemic Treatment and Avelumab Maintenance in US Patients with Locally Advanced or Metastatic Urothelial Carcinoma: The SPEAR Bladder-II Study.

Avelumab first-line maintenance (1LM) is approved for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) who do not have disease progression after platinum-based chemotherapy (PBC). This retrospective study describes real-world treatment patterns and clinical outcomes in pati...

Full description

Bibliographic Details

Published in:	Current Oncology Vol. 32; no. 4; pp. 187 - 201
Main Authors:	Sura, Sneha, Bupathi, Manojkumar, Morris, Valerie, Conkling, Paul, Todoroff, Karen, Bhanegaonkar, Abhijeet, Ike, Chiemeka
Format:	Journal Article
Published:	MDPI Apr2025
Online Access:	View this record in EBSCOhost